Mathieu C, Wych J, Hendriks AEJ, Van Ryckeghem L, et al. Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet 2025 Sep 18:S0140-6736(25)01674-5. doi: 10.1016/S0140-6736(25)01674.
PMID: 40976248